This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
‘Three Pillar’ Strategic Update
Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM.
The recent identification of Bisantrene as a potent inhibitor of the Fat and obesity associated (FTO) protein, together with the outstanding results from the Sheba Medical Centre Phase II trial of Bisantrene in R/R acute myeloid leukemia (AML), required a revaluation of the previous 5-path strategy to maximise shareholder value.
CEO/Managing Director, Phil Lynch commented, “2019-2020 has been a pivotal period for Race. New data on Bisantrene’s potential as both a highly targeted precision oncology drug and as a better chemotherapeutic approach led the Board to examine and refine our strategy. We are pleased to share our new Three Pillar strategy, which positions Bisantrene as a much higher value and multi-faceted transactional opportunity and is designed to deliver better therapeutic alternatives for patients across a range of cancer types.”
A longer form video presentation will be released to shareholders during the week commencing 7 December 2020.